![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAGEB10 |
Gene summary for MAGEB10 |
![]() |
Gene information | Species | Human | Gene symbol | MAGEB10 | Gene ID | 139422 |
Gene name | MAGE family member B10 | |
Gene Alias | MAGEB10 | |
Cytomap | Xp21.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q96LZ2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
139422 | MAGEB10 | HCC1 | Human | Liver | HCC | 7.19e-14 | 9.30e-01 | 0.5336 |
139422 | MAGEB10 | HCC2 | Human | Liver | HCC | 1.12e-12 | 6.89e-01 | 0.5341 |
139422 | MAGEB10 | HCC5 | Human | Liver | HCC | 1.75e-08 | 8.45e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAGEB10 | SNV | Missense_Mutation | novel | c.563G>A | p.Cys188Tyr | p.C188Y | Q96LZ2 | protein_coding | tolerated(1) | benign(0.017) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAGEB10 | SNV | Missense_Mutation | rs779588937 | c.125N>T | p.Ala42Val | p.A42V | Q96LZ2 | protein_coding | tolerated(0.13) | benign(0.077) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAGEB10 | SNV | Missense_Mutation | c.97N>A | p.Glu33Lys | p.E33K | Q96LZ2 | protein_coding | deleterious(0.05) | benign(0.023) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MAGEB10 | SNV | Missense_Mutation | rs867759826 | c.763N>A | p.Glu255Lys | p.E255K | Q96LZ2 | protein_coding | tolerated(0.17) | possibly_damaging(0.763) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAGEB10 | SNV | Missense_Mutation | novel | c.305N>A | p.Ala102Asp | p.A102D | Q96LZ2 | protein_coding | tolerated(0.09) | benign(0) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAGEB10 | SNV | Missense_Mutation | novel | c.176N>C | p.Asn59Thr | p.N59T | Q96LZ2 | protein_coding | tolerated(0.29) | benign(0.023) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAGEB10 | SNV | Missense_Mutation | novel | c.112N>C | p.Ser38Pro | p.S38P | Q96LZ2 | protein_coding | tolerated(0.27) | benign(0.01) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAGEB10 | SNV | Missense_Mutation | c.113N>A | p.Ser38Tyr | p.S38Y | Q96LZ2 | protein_coding | tolerated(0.76) | benign(0.017) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD | |
MAGEB10 | SNV | Missense_Mutation | novel | c.221C>T | p.Ala74Val | p.A74V | Q96LZ2 | protein_coding | deleterious(0.04) | possibly_damaging(0.596) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MAGEB10 | SNV | Missense_Mutation | novel | c.568N>A | p.Ala190Thr | p.A190T | Q96LZ2 | protein_coding | tolerated(0.06) | benign(0.098) | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |